Akihiro Nishiyama1, Yukiko Staub2, Yukio Suga2, Mikiya Fujita2, Azusa Tanimoto3, Koushiro Ohtsubo3, Seiji Yano3. 1. Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; an0510@staff.kanazawa-u.ac.jp. 2. Department of Clinical Pharmacy and Healthcare Sciences, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan. 3. Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Abstract
BACKGROUND/AIM: Reportedly, sarcopenia and nutritional status are associated with prognosis in cancer patients. However, data regarding the relationship of these factors with advanced thyroid cancer patients receiving molecular targeted therapy remains scarce. Therefore, we investigated the relationship between nutritional assessment, as well as sarcopenia, and prognosis in patients with advanced thyroid cancer undergoing molecular targeted therapy. PATIENTS AND METHODS: In this retrospective study, sarcopenia and several markers of nutritional status were assessed in advanced thyroid cancer patients at the Kanazawa University Hospital, before the introduction of molecular targeted therapy. RESULTS: Advanced thyroid cancer patients with sarcopenia presented a worse prognosis than those without sarcopenia. Additionally, sarcopenia strongly correlated with several markers of nutritional status, such as albumin, prognostic nutrition index, and Glasgow prognostic score. CONCLUSION: Sarcopenia could be a prognostic factor in patients with advanced thyroid cancer receiving molecular targeted therapy. Copyright
BACKGROUND/AIM: Reportedly, sarcopenia and nutritional status are associated with prognosis in cancer patients. However, data regarding the relationship of these factors with advanced thyroid cancer patients receiving molecular targeted therapy remains scarce. Therefore, we investigated the relationship between nutritional assessment, as well as sarcopenia, and prognosis in patients with advanced thyroid cancer undergoing molecular targeted therapy. PATIENTS AND METHODS: In this retrospective study, sarcopenia and several markers of nutritional status were assessed in advanced thyroid cancer patients at the Kanazawa University Hospital, before the introduction of molecular targeted therapy. RESULTS: Advanced thyroid cancer patients with sarcopenia presented a worse prognosis than those without sarcopenia. Additionally, sarcopenia strongly correlated with several markers of nutritional status, such as albumin, prognostic nutrition index, and Glasgow prognostic score. CONCLUSION: Sarcopenia could be a prognostic factor in patients with advanced thyroid cancer receiving molecular targeted therapy. Copyright
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Erin L Van Blarigan; Charles S Fuchs; Donna Niedzwiecki; Sui Zhang; Leonard B Saltz; Robert J Mayer; Rex B Mowat; Renaud Whittom; Alexander Hantel; Al Benson; Daniel Atienza; Michael Messino; Hedy Kindler; Alan Venook; Shuji Ogino; Edward L Giovannucci; Kimmie Ng; Jeffrey A Meyerhardt Journal: JAMA Oncol Date: 2018-06-01 Impact factor: 31.777
Authors: Jun Choul Lee; Byong-Sop Song; Young Mi Kang; Yu-Ri Kim; Yea Eun Kang; Ju Hee Lee; Minho Shong; Hyon-Seung Yi Journal: Front Endocrinol (Lausanne) Date: 2021-11-10 Impact factor: 5.555